<p>今年下半年，首次公开募股（IPO）活动回暖，科技和医疗保健行业在上市中继续占据主导地位。这一复苏得益于较低的利率和强劲的股市。Lumexa Imaging Holdings 是一家运营门诊医疗扫描中心的公司，是最新一家寻求首次公开募股的医疗公司。在最近向证券交易委员会提交的文件中，该公司透露计划发行约 2500 万股，价格区间为每股 17.0 美元至 20.0 美元。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.news.alphastreet.com/wp-content/uploads/2019/04/IPO-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.news.alphastreet.com/wp-content/uploads/2019/04/IPO-1.jpg"/></p>
<h2>发行情况</h2>
<p>Lumexa 已申请在纳斯达克证券交易所上市，股票代码为_LMRI_。承销团由巴克莱银行、摩根大通和杰富瑞领导。<strong>预计股票发行在估计价格区间中点的情况下，产生约 4.27 亿美元的收益（扣除费用后）</strong>。管理层打算将收益用于偿还部分公司未偿债务和用于营运资金。预计在 IPO 后将有约 9460 万股流通，公司的目标估值高达 18.9 亿美元。</p>
<p><strong><em>另请阅读：</em> Costco 2026 财年第一季度财报预览</strong></p>
<p>截至 2025 年 9 月 30 日的九个月，Lumexa 报告总收入为 7.553 亿美元，而去年同期为 7.008 亿美元。该公司在这九个月内录得净亏损 1840 万美元，较去年同期的 6900 万美元亏损有所改善。运营收入在此期间翻了一番，达 8360 万美元。</p>
<h2>业务概况</h2>
<p>Lumexa 是美国领先的先进诊断服务提供商，提供 MRI、CT 和乳腺 X 光检查，拥有庞大的网络。公司成立于 2018 年，目前由首席执行官 Caitlin Zulla 领导。<strong>自成立以来，Lumexa 已完成 20 项收购，并开设了 41 个_新建_中心，这些中心是现代化的、公司拥有的独立门诊影像设施。</strong> 据估计，_诊断影像服务_市场在 2019 年至 2024 年间以 4.2% 的复合年增长率增长，独立影像中心的增长率为 6.9%。</p>
<p>首次公开募股新闻：Lumexa Imaging 上市时需要关注的事项首次出现在 AlphaStreet 上。</p>

巴克莱银行

纳斯达克 OMX 交易所

<p>Lumexa Imaging Holdings 计划上市，拟发行 2500 万股，价格在每股 17 至 20 美元之间，目标筹集 4.27 亿美元。此次首次公开募股将在纳斯达克上市，股票代码为 LMRI，由巴克莱银行、JP 摩根和杰富瑞管理。筹集的资金将用于偿还债务和资助营运资金。Lumexa 报告截至 2025 年 9 月的九个月内收入为 7.553 亿美元，净亏损为 1840 万美元，较去年有所改善</p>

<p>IPO activity rebounded in the second half of the year, with the technology and healthcare sectors maintaining their dominance in public listings. The recovery has been supported by lower interest rates and a strong equity market. Lumexa Imaging Holdings, an operator of outpatient medical scanning centers, is the latest healthcare firm to pursue an initial public offering. In a recent filing with the Securities and Exchange Commission, the company revealed plans to offer around 25 million shares, priced between $17.0 per share and $20.0 per share.</p>
<div class="lb-trans"><p>今年下半年，首次公开募股（IPO）活动回暖，科技和医疗保健行业在上市中继续占据主导地位。这一复苏得益于较低的利率和强劲的股市。Lumexa Imaging Holdings 是一家运营门诊医疗扫描中心的公司，是最新一家寻求首次公开募股的医疗公司。在最近向证券交易委员会提交的文件中，该公司透露计划发行约 2500 万股，价格区间为每股 17.0 美元至 20.0 美元。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.news.alphastreet.com/wp-content/uploads/2019/04/IPO-1.jpg" alt="" original-src="https://cdn.news.alphastreet.com/wp-content/uploads/2019/04/IPO-1.jpg"/></p>
<h2>The Offering</h2>
<div class="lb-trans"><h2>发行情况</h2>
</div><p>Lumexa has applied to list on the Nasdaq stock exchange under the symbol <em>LMRI</em>. The group of underwriters managing the offering is led by Barclays, JP Morgan, and Jefferies. <strong>The stock offering is expected to generate proceeds of around $427.0 million – after deducting charges – at the midpoint of the estimated price range</strong>. The management intends to use the proceeds to repay a portion of the company’s outstanding debt and for working capital. With around 94.6 million shares expected to be outstanding post-IPO, the company targets a valuation of up to $1.89 billion.</p>
<div class="lb-trans"><p>Lumexa 已申请在纳斯达克证券交易所上市，股票代码为_LMRI_。承销团由巴克莱银行、摩根大通和杰富瑞领导。<strong>预计股票发行在估计价格区间中点的情况下，产生约 4.27 亿美元的收益（扣除费用后）</strong>。管理层打算将收益用于偿还部分公司未偿债务和用于营运资金。预计在 IPO 后将有约 9460 万股流通，公司的目标估值高达 18.9 亿美元。</p>
</div><p><strong><em>Also Read:</em> Costco Q1 FY26 Earnings Preview</strong></p>
<div class="lb-trans"><p><strong><em>另请阅读：</em> Costco 2026 财年第一季度财报预览</strong></p>
</div><p>For the nine months ended September 30, 2025, Lumexa reported total revenues of $755.3 million, compared to $700.8 million in the corresponding period last year. The company posted a net loss of $18.4 million for the nine months, an improvement from the prior-year period when it incurred a loss of $69.0 million. Income from operations more than doubled to $83.6 million during the period.</p>
<div class="lb-trans"><p>截至 2025 年 9 月 30 日的九个月，Lumexa 报告总收入为 7.553 亿美元，而去年同期为 7.008 亿美元。该公司在这九个月内录得净亏损 1840 万美元，较去年同期的 6900 万美元亏损有所改善。运营收入在此期间翻了一番，达 8360 万美元。</p>
</div><h2>The Business</h2>
<div class="lb-trans"><h2>业务概况</h2>
</div><p>Lumexa is a leading provider of advanced diagnostics like MRI, CT, and mammography in the US through a large network. Founded in 2018, the company is currently led by chief executive officer Caitlin Zulla. <strong>Since its inception, Lumexa has completed 20 acquisitions and opened 41 <em>de novo</em> centers, which are modern, company-owned, standalone outpatient imaging facilities.</strong> It is estimated that the <em>diagnostic imaging services</em> market grew at a compound annual rate of 4.2% from 2019 to 2024, led by freestanding imaging center growth of 6.9%.</p>
<div class="lb-trans"><p>Lumexa 是美国领先的先进诊断服务提供商，提供 MRI、CT 和乳腺 X 光检查，拥有庞大的网络。公司成立于 2018 年，目前由首席执行官 Caitlin Zulla 领导。<strong>自成立以来，Lumexa 已完成 20 项收购，并开设了 41 个_新建_中心，这些中心是现代化的、公司拥有的独立门诊影像设施。</strong> 据估计，_诊断影像服务_市场在 2019 年至 2024 年间以 4.2% 的复合年增长率增长，独立影像中心的增长率为 6.9%。</p>
</div><p>The post IPO News: What to look for when Lumexa Imaging goes public first appeared on AlphaStreet.</p>
<div class="lb-trans"><p>首次公开募股新闻：Lumexa Imaging 上市时需要关注的事项首次出现在 AlphaStreet 上。</p>
</div>

IPO 新闻：Lumexa Imaging 上市时需要注意哪些事项